Literature DB >> 17613966

Efficacy and safety of aripiprazole in alcohol dependence.

Giovanni Martinotti1, Marco Di Nicola, Luigi Janiri.   

Abstract

Dopaminergic agonists and antagonists have both been examined for the treatment of substance abuse with contrasting results. To the best of our knowledge dopamine receptor partial agonists have not been investigated in alcohol use disorders. Thirteen detoxified alcohol-dependent subjects were treated with flexible doses of aripiprazole for 16 weeks. Six patients maintained an alcohol free condition for all the study period. All the subjects experienced a reduction of craving in both OCDS (p < .05) and VAS (p < .05), and a decrease of the SCL-90 General Severity Index (GSI) (p < .05). The data of this pilot clinical study, suggest a possible role for this drug in the treatment of individuals with alcohol problems.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17613966     DOI： 10.1080/00952990701313660

Source DB:  PubMed          Journal:  Am J Drug Alcohol Abuse        ISSN： 0095-2990            Impact factor:   3.829


  13 in total

1.  Evolution of Substance use, Neurological and Psychiatric Symptoms in Schizophrenia and Substance use Disorder Patients: A 12-Week, Pilot, Case-Control Trial with Quetiapine.

Authors:  Simon Zhornitsky; Emmanuel Stip; Joelle Desfossés; Tania Pampoulova; Elie Rizkallah; Pierre-Paul Rompré; Lahcen Aït Bentaleb; Olivier Lipp; Jean-Pierre Chiasson; Alain Gendron; Stéphane Potvin
Journal:  Front Psychiatry       Date:  2011-05-13       Impact factor: 4.157

2.  Treatment with aripiprazole and levetiracetam in a subject with binge drinking disorder: a case report.

Authors:  Vincenzo M Romeo; Antonio Bruno; Umberto Micò; Rocco A Zoccali; Maria Rosaria A Muscatello
Journal:  Innov Clin Neurosci       Date:  2013-01

Review 3.  From gene networks to drugs: systems pharmacology approaches for AUD.

Authors:  Laura B Ferguson; R Adron Harris; Roy Dayne Mayfield
Journal:  Psychopharmacology (Berl)       Date:  2018-03-01       Impact factor: 4.530

4.  Change in moderate alcohol consumption and quality of life: evidence from 2 population-based cohorts.

Authors:  Xiaoxin I Yao; Michael Y Ni; Felix Cheung; Joseph T Wu; C Mary Schooling; Gabriel M Leung; Herbert Pang
Journal:  CMAJ       Date:  2019-07-08       Impact factor: 8.262

5.  Adjunctive aripiprazole therapy with escitalopram in patients with co-morbid major depressive disorder and alcohol dependence: clinical and neuroimaging evidence.

Authors:  Doug Hyun Han; Sun Mi Kim; Jung Eun Choi; Kyung Joon Min; Perry F Renshaw
Journal:  J Psychopharmacol       Date:  2013-01-16       Impact factor: 4.153

Review 6.  Pharmacological approaches to reducing craving in patients with alcohol use disorders.

Authors:  Carolina L Haass-Koffler; Lorenzo Leggio; George A Kenna
Journal:  CNS Drugs       Date:  2014-04       Impact factor: 5.749

Review 7.  Molecular basis of alcoholism.

Authors:  Dana Most; Laura Ferguson; R Adron Harris
Journal:  Handb Clin Neurol       Date:  2014

8.  Effects of aripiprazole on subjective and physiological responses to alcohol.

Authors:  Henry R Kranzler; Jonathan Covault; Amira Pierucci-Lagha; Grace Chan; Kara Douglas; Albert J Arias; Cheryl Oncken
Journal:  Alcohol Clin Exp Res       Date:  2008-02-08       Impact factor: 3.455

9.  Comparing and Combining Topiramate and Aripiprazole on Alcohol-Related Outcomes in a Human Laboratory Study.

Authors:  Carolina L Haass-Koffler; Kimberly Goodyear; William H Zywiak; Lorenzo Leggio; George A Kenna; Robert M Swift
Journal:  Alcohol Alcohol       Date:  2018-05-01       Impact factor: 2.826

10.  Anhedonia and substance dependence: clinical correlates and treatment options.

Authors:  Daniele Stavros Hatzigiakoumis; Giovanni Martinotti; Massimo Di Giannantonio; Luigi Janiri
Journal:  Front Psychiatry       Date:  2011-03-17       Impact factor: 4.157
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.